FOXP3 and graft versus host disease: The objective of the present study was to identify a BETi which did not interfere in vivo with CD4+FoxP3+ regulatory T cell (Treg) expansion and function so it could be utilized together with Tregs following aHSCT to ameliorate graft-versus-host disease (GVHD).